Kite Pharma
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
2400 Broadway, Santa Monica, California,...Phone Number
(310) 824-9999Website
www.kitepharma.comRevenue
$675.1 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
7
7
1
2
2
2
About Kite Pharma
Kite Pharma, founded in 2009, is a pharmaceutical company specializing in cell therapy to treat and potentially cure cancer. The company focuses on engineered T cell therapy for hematologic malignancies and is committed to making these innovative treatments accessible to eligible patients. Unlike traditional pharmaceutical manufacturing, Kite Pharma's approach involves reengineering a patient's own immune cells to fight cancer cells individually. The company operates dedicated cell therapy manufacturing facilities in California, Maryland, and the Netherlands, with corporate headquarters in Santa Monica, California. Kite Pharma continues to advance cancer immunotherapy through its specialized treatments and research.Explore more
Kite Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kite Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Kite Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Kite Pharma has recently received funding, and reach out quickly before it becomes old news!
Click to see if Kite Pharma had a recent Job posting/layoffs
Earning: See what the market has to say on Kite Pharma recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Kite Pharma
Website visits: Recent activity has been detected on your website
Check out if Kite Pharma is spiking on competitors!
Product Launch: Get notified when Kite Pharma launches new products
Funding: Get notified immidiatlly once Kite Pharma has new funding data
Recommended Actions
Reach out to Masked Content who joined Kite Pharma as Masked Content
Find 2 more new buyers
Compare Similar Companies to Kite Pharma
Compare insights from companies similar to Kite Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$673M
1K - 5K
Public
$1.6B
2010
AM
Alyssa MooreChief of Staff and Head Senior Vice President, Program and Portfolio Management
Company Profile Activity
Activity Insights
Kite Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Kite Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Kite Pharma.
Kite Pharma financials insights
Gather financial insights about Kite Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Private Equity
$12.5M
2013
Series A
$35M
2014
Debt
$50M
Stock Offering
$127.5M
Kite Pharma Tech Stack
A closer look at the technologies used by Kite Pharma
See more technologies
Most Recent Scoops
Hiring Plans
Kite Pharma has more open roles in Legal than it has had at any time in the past 12 months. Technologies mentioned include: Remote.
Hiring Plans
Open Position
Open Position
Open Position
Open Position
Kite Pharma News & Media
Cellares Announces Agreement with Kite to Evaluate Its Cell Shuttle Automated Manufacturing Platform
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, today announced that Kite, a Gilead Company, will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle. The data generated in this proof-of-concept evaluation will be utilized to assess viability of the Cell Shuttle as a future manufacturing option for Kite. “This agreement with KiteCell therapy weekly: Leveraging CRISPR-Cas3 to treat epidermolysis bullosa - RegMedNet
In this week's round-up: Healiva (Lugano, Switzerland) and C4U Corporation (Osaka, Japan) have formed a strategic alliance to develop CRISPR-Cas3-based gene therapy for epidermolysis bullosa.Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc., a Gilead Company (Nasdaq: GILD), today announced that the Marketing Authorization in Japan for Yescarta® (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, has been transferred from Daiichi Sankyo Co., Ltd. to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc. This follows the announcement made by Daiichi Sankyo and Kite Pharma, Inc. in December 2022 about changes to their initial 2017 partnershYescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma
SANTA MONICA, Calif. & TOKYO--(BUSINESS WIRE)--Kite Pharma, Inc., a Gilead Company, (hereafter, Kite) (NASDAQ: GILD) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) (TSE: 4568) today jointly announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has approved Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, for the initial treatment of patients with relapsed/refractory large B-cell lymphoma ( R/R LBCL): diffuse large B-cell lymphoma,
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Kite Pharma
Sign Up For FreeTo access detailed company insights
Kite Pharma, founded in 2009, is a pharmaceutical company specializing in cell therapy to treat and potentially cure cancer. The company focuses on engineered T cell therapy for hematologic malignancies and is committed to making these innovative treatments accessible to eligible patients. Unlike traditional pharmaceutical manufacturing, Kite Pharm... Read More
